Shares of Merus N.V. (MRUS) are up nearly 15% at $47.74 in premarket trading Friday, following encouraging interim clinical data from the ongoing phase II trial of Petosemtamab in combination with Merck's Keytruda in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Petosemtamab, the company's lead drug candidate, is a human IgG1 Biclonics designed to bind to cancer cells expressing epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5).
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.